InsidersTradesSigma
Follow the SPYRE THERAPEUTICS INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Market capitalisation: €8.5bn. The latest transaction was filed on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: CAMERON TURTLE. All data is openly available.
Analysts rate SPYRE THERAPEUTICS INC Strong Buy (bullish), based on 15 analysts. Average price target: US$101.53.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
SPYRE THERAPEUTICS INC is a company focused on developing innovative therapies for serious diseases. It is listed on the XNAS market.